참고문헌
- Bernstein ML, Leclerc JM, Bunin G, et al (1992). A populationbased study of neuroblastoma incidence, survival, and mortality in North America. J Clin Oncol, 10, 323-9.
- Bhatnagar SN, Sarin YK (2012). Neuroblastoma: a review of management and outcome. Indian J Pediatrics, 79, 787-92. https://doi.org/10.1007/s12098-012-0748-2
- Brodeur GM (2011). Knowing your ABCCs: novel functions of ABCC transporters. J Natl Cancer Inst, 103, 1207-8. https://doi.org/10.1093/jnci/djr277
- Chen QR, Song YK, Wei JS, et al (2008). An integrated crossplatform prognosis study on neuroblastoma patients. Genomics, 92, 195-203. https://doi.org/10.1016/j.ygeno.2008.05.014
- Cornero A, Acquaviva M, Fardin P, et al (2012). Design of a multi-signature ensemble classifier predicting neuroblastoma patients' outcome. BMC Bioinformatics, 13, 13. https://doi.org/10.1186/1471-2105-13-13
- David L, Baker MLS, Susan L, et al (2010). Outcome after reduced chemotherapy for intermediate-risk neuroblastoma. N Engl J Med, 363, 1313-23. https://doi.org/10.1056/NEJMoa1001527
- Hara J ( 2012). Development of treatment strategies for advanced neuroblastoma. Int J Clinical Oncology, 17, 196-203. https://doi.org/10.1007/s10147-012-0417-5
- Harder T, Plagemann A, Harder A (2010). Birth weight and risk of neuroblastoma:a meta-analysis. Int J Epidemiol, 39, 746-56. https://doi.org/10.1093/ije/dyq040
- Henderson TO, Bhatia S, Pinto N, et al (2011). Racial and ethnic disparities in risk and survival in children with neuroblastoma: a children's oncology group study. J Clin Oncol, 29, 76-82. https://doi.org/10.1200/JCO.2010.29.6103
- Hiyama E (2008). Neuroblastoma screening in Japan: populationbased cohort study and future aspects of screening. Ann Acad Med Singapore, 37, 88-91.
- Lee A (2012). Neuroblastoma: the challenge remains. Singapore Med J, 53, 1-2.
- Ries LAG, Krapcho M, Mariotto A, et al (2007). SEER cancer statistics review, 1975-2004. National Cancer Institute, 2007.
- Schilling FH, Spix C, Berthold F, et al (2002). Neuroblastoma screening at one year of age. N Engl J Med, 346, 1047-53. https://doi.org/10.1056/NEJMoa012277
- Stat B (2011). Neuroblastoma: five-year survival. J Natl Cancer Inst, 103, 1220. https://doi.org/10.1093/jnci/djr320
- Sung KW, Ahn HS, Cho B, et al (2010). Efficacy of tandem high-dose chemotherapy and autologous stem cell rescue in patients over 1 year of age with stage 4 neuroblastoma: the Korean Society of Pediatric Hematology-Oncology experience over 6 years (2000-2005). J Korean Med Sci, 25, 691-7. https://doi.org/10.3346/jkms.2010.25.5.691
- Tan C, Sabai SM, Tin AS, Quah TC, Aung L (2012), Neuroblastoma: experience from National University Health System, Singapore (1987-2008). Singapore Med J, 53, 19-25.
- Vermeulen J, De Preter K, Naranjo A, et al (2009). Outcome Prediction of children with neuroblastoma using a multigene expression signature, a retrospective SIOPEN/COG/GPOH study. Lancet Oncol, 10, 663-71. https://doi.org/10.1016/S1470-2045(09)70154-8
- Weinstein JL, Katzenstein HM, Cohn SL (2003). Advances in the diagnosis and treatment of neuroblastoma. Oncologist, 8, 278-92. https://doi.org/10.1634/theoncologist.8-3-278
- Wiangnon S, Veerakul G, Nuchprayoon I, et al (2011). Childhood cancer incidence and survival 2003-2005, Thailand: study from the Thai pediatric oncology group. Asian Pac J Cancer Prev, 12, 2215-20.
피인용 문헌
- Epidemiologic Survey of Infantile Cancer in Iran based on the Data of the Largest Pediatric Cancer Referral Center (Ali-Asghar Children Hospital), 1996-2005 vol.15, pp.3, 2014, https://doi.org/10.7314/APJCP.2014.15.3.1211
- Expression of Ki-67, p53 and VEGF in Pediatric Neuroblastoma vol.15, pp.7, 2014, https://doi.org/10.7314/APJCP.2014.15.7.3065
- Clinicopathological Features of Adrenal Tumors: a Ten-year Study in Yazd, Iran vol.16, pp.12, 2015, https://doi.org/10.7314/APJCP.2015.16.12.5031
- A Phase I Study of the Anti-Idiotype Vaccine Racotumomab in Neuroblastoma and Other Pediatric Refractory Malignancies vol.62, pp.12, 2015, https://doi.org/10.1002/pbc.25631
- Update on Adrenal Tumours in 2017 World Health Organization (WHO) of Endocrine Tumours vol.28, pp.3, 2017, https://doi.org/10.1007/s12022-017-9484-5